March 9 (Reuters) - The U.S. health regulator issued a draft guidance on Monday to help drugmakers develop cheaper versions ...

The Trump administration launched a drug pricing initiative offering immediate savings, but experts debated whether lower ...

The FDA has proposed new rules to speed up the development of biosimilar drugs, aiming to reduce the costs of biologic ...

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current ...

In a recently published review, a research team led by MedUni Vienna has highlighted a promising new approach to drug ...

In this week’s edition of InnovationRx, we look at cheaper biologic drugs, Novo Nordisk’s $2 billion next-gen obesity drug deal, new ways of fighting cancer, and more.

Machine-learning drug development company Insitro has inked three agreements with Eli Lilly for new medicines for metabolic diseases. But the deal is a little different compared to many recent deals ...

Artificial intelligence has moved from pilot projects to a central role in many life sciences strategies. What began as a set ...

Researchers have applied AI and machine learning to every stage of the drug development process. This includes identifying targets in the body, screening potential candidates, designing drug molecules ...

Makary pointed to three bottlenecks: hospital contracting; ethical reviews and approvals; and the Investigational New Drug ...

Oxana Iliach is a Senior Director of Regulatory Strategy at Certara (PA, USA), a biotech company that offers comprehensive solutions for transforming and accelerating drug development. In her spare ...

Xenon Pharmaceuticals said its treatment for a common type of seizure disorder significantly reduced the frequency of those seizures compared to a placebo.